Paul Juneau - Concepedia

Author

Paul Juneau

Truven Health Analytics (United States)ORCID

Also Known As

P Juneau, P. Juneau, P. L. JUNEAU, P. L. Juneau, P.L Juneau, P.L. Juneau, Paul Juneau, Paul L Juneau, Paul L. Juneau

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Truven Health Analytics (United States)Sinai Hospital Wayne State University National Institutes of Health Office of Research Services

About

Paul Juneau is an author at Truven Health Analytics (United States) specializing in medicine, pharmacology, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	1.2K
2	Social Sciences	4	4	84
3	Health Sciences	2	2	72
4	Biomedical Engineering	1	1	34
5	Cell Biology	1	1	26

Paul Juneau

Publications

Citations

H-Index

Page 1

	Year	Citations
Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis Susan E. Bove, Salvatore Calcaterra, Rachel M. Brooker, Osteoarthritis and Cartilage InflammationWeight BearingRheumatoid DisorderAnti-inflammatoryMedicine	2003	497
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy Kathryn R. Wagner, James L. Fleckenstein, Anthony A. Amato, Annals of Neurology	2008	457
Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions David A. Loeffler, James R. Connor, Paul Juneau, Journal of Neurochemistry	1995	334
Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders David A. Loeffler, Peter A. LeWitt, Paul Juneau, Brain Research Neurodegenerative DiseasesNeurological DisorderNeuroanatomyMedicineNeurology	1996	234
Predictors of medication adherence in patients with type 2 diabetes mellitus Suellen M. Curkendall, Nina Thomas, Kelly Bell, Current Medical Research and Opinion	2013	135
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: <scp>H</scp> igher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide Carlos Alatorre, Laura Fernández Landó, Maria Yu, Diabetes Obesity and Metabolism	2017	106
Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States Emily Durden, Lionel Pinto, Lorena López-González, Archives of Osteoporosis	2017	87
Ceruoplasmin Is Increased in Cerebrospinal Fluid in Alzheimerʼs Disease but Not Parkinsonʼs Disease David A. Loeffler, A. J. DeMaggio, Paul Juneau, Alzheimer Disease & Associated Disorders	1994	78
Natural killer‐cell activity under conditions reflective of tumor micro‐environment David A. Loeffler, Gloria H. Heppner, Paul Juneau International Journal of Cancer	1991	71
The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age‐related comorbidities in the United States Emily Durden, David Walker, Stephani Gray, Neurourology and Urodynamics	2018	67

Page 1